Trials / Sponsors / Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc.
Industry · 3 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EG Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM | Phase 2 | 2026-04-01 |
| Active Not Recruiting | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With E Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | 2022-03-31 |
| Terminated | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Solid Tumor | Phase 1 | 2019-12-19 |